US Broker Ratings

Progyny, Inc. (PGNY) Stock Analysis: Exploring the 11.84% Upside Potential in Healthcare Plans

Progyny, Inc. (NASDAQ: PGNY) has emerged as a compelling player within the healthcare sector, specifically focusing on the niche of fertility and family building benefits management. Headquartered in New York..

Tarsus Pharmaceuticals, Inc. (TARS) Stock Analysis: A 78% Upside Potential in Biotech

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) is capturing the attention of savvy investors with a compelling narrative in the biotechnology sector. As a leading player in the field of eye care,..

Alphatec Holdings, Inc. (ATEC) Stock Analysis: A Healthcare Play with 67.9% Upside Potential

Alphatec Holdings, Inc. (NASDAQ: ATEC) stands as a noteworthy player in the healthcare sector, specializing in medical devices that cater to the surgical treatment of spinal disorders. With a market..

PTC Therapeutics, Inc. (PTCT) Stock Analysis: A Biotech Powerhouse with a 27% Potential Upside

PTC Therapeutics, Inc. (NASDAQ: PTCT) is capturing investor attention with its promising growth prospects and robust pipeline in the biotechnology sector. With a market capitalization of $3.92 billion, this New..

Denali Therapeutics Inc. (DNLI) Stock Analysis: Exploring the 119% Potential Upside Amid Strong Buy Ratings

For investors eyeing opportunities in the biotechnology sector, Denali Therapeutics Inc. (DNLI) presents a compelling case with its innovative approach to treating neurodegenerative diseases. Headquartered in South San Francisco, California,..

Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis: A 39.55% Potential Upside Beckons Investors

Amneal Pharmaceuticals, Inc. (AMRX), a prominent player in the healthcare sector, is garnering attention from investors due to its substantial potential upside. With a market capitalization of $3.92 billion and..

CG Oncology, Inc. (CGON) Investor Outlook: Analyzing a 132.95% Potential Upside in Biotech

CG Oncology, Inc. (CGON), a prominent player in the biotechnology sector, is capturing investor attention with its compelling potential upside of 132.95%. This late-stage clinical biopharmaceutical company is focused on..

Sotera Health Company (SHC) Stock Analysis: Navigating a 24.89% Potential Upside in Healthcare

Sotera Health Company (NASDAQ: SHC) stands out in the healthcare sector, particularly in the diagnostics and research industry. With a market capitalization of $3.3 billion, this Ohio-based company is a..

Select Medical Holdings Corp (SEM) Stock Analysis: A 37% Upside Potential with Strong Buy Ratings

Select Medical Holdings Corporation (NYSE: SEM), a prominent player in the healthcare sector, is capturing investor attention not only with its robust market position but also with a compelling potential..

Metsera, Inc. (MTSR) Stock Analysis: Exploring a Potential 29.50% Upside in the Biotech Industry

For investors seeking opportunities in the burgeoning field of biotechnology, Metsera, Inc. (NASDAQ: MTSR) presents an intriguing prospect. With its focus on developing innovative treatments for obesity and related metabolic..

Veracyte, Inc. (VCYT) Stock Analysis: Unpacking the 53% Upside Potential

For investors navigating the healthcare sector, Veracyte, Inc. (NASDAQ: VCYT) presents an intriguing case with its robust growth potential and a substantial upside forecasted by analysts. Operating within the diagnostics..

Surgery Partners, Inc. (SGRY) Stock Analysis: Exploring a 39.58% Potential Upside for Investors

Surgery Partners, Inc. (NASDAQ: SGRY), a prominent player in the healthcare sector specializing in medical care facilities, offers an intriguing investment opportunity. With a market capitalization of $2.88 billion, this..

GeneDx Holdings Corp. (WGS) Stock Analysis: Exploring a 25.88% Potential Upside in Genomics Innovation

GeneDx Holdings Corp. (NASDAQ: WGS) is making waves in the healthcare sector, specifically within the diagnostics and research industry. Based in Stamford, Connecticut, GeneDx specializes in pediatric and rare disease..

Concentra Group Holdings Parent (CON) Stock Analysis: A Healthcare Powerhouse with 38% Upside Potential

For investors seeking opportunities in the healthcare sector, Concentra Group Holdings Parent (NASDAQ: CON) emerges as a compelling candidate. With a market capitalization of $2.59 billion, Concentra operates within the..

DENTSPLY SIRONA Inc. (XRAY) Stock Analysis: Insights into Its 13.39% Potential Upside

For investors seeking opportunities in the healthcare sector, DENTSPLY SIRONA Inc. (NASDAQ: XRAY) presents a compelling case with its diverse offerings in dental and healthcare consumables. Despite its recent challenges,..

Alvotech (ALVO) Stock Analysis: Exploring a 101% Potential Upside in the Biosimilar Market

Alvotech (NASDAQ: ALVO), a Luxembourg-based biosimilar manufacturer, is capturing investor attention with its impressive 101.12% potential upside, as per analyst targets. With a market cap of $2.75 billion, the company..

LifeStance Health Group, Inc. (LFST) Stock Analysis: Exploring a 93.81% Potential Upside

LifeStance Health Group, Inc. (NASDAQ: LFST) has captured the attention of investors with its intriguing potential upside of 93.81%. As a pivotal player in the healthcare sector, focusing on outpatient..

Envista Holdings Corporation (NVST) Stock Report: Navigating a -4.93% Potential Downside Amidst Mixed Analyst Ratings

Envista Holdings Corporation (NYSE: NVST), a prominent player in the healthcare sector specializing in dental products, presents a complex investment profile for potential investors. With a market capitalization of $3.39..

Warby Parker Inc. (WRBY) Investor Outlook: Navigating Strong Revenue Growth Amid Challenges

Warby Parker Inc. (NYSE: WRBY), a leading eyewear retailer headquartered in New York, has carved a niche in the healthcare sector, specifically within the medical instruments and supplies industry. With..

Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Strong Buy Ratings Signal a Promising 24.93% Upside Potential

Protagonist Therapeutics, Inc. (PTGX) has caught the attention of investors with its pronounced potential for growth within the biotechnology sector. Headquartered in Newark, California, this biopharmaceutical company specializes in developing..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds